MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

International Immunopharmacology

Volumn 11, Issue 7, 2011, Pages 856-861

  Finke, James ^a   Ko, Jennifer ^a,b   Rini, Brian ^b   Rayman, Pat ^a   Ireland, Joanna ^a   Cohen, Peter ^c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

MDSCs; Tyrosin kinase inhibitor; VEGFRs

Indexed keywords

GAMMA INTERFERON; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; NEUTROPHIL COLLAGENASE; STAT5 PROTEIN; STROMAL CELL DERIVED FACTOR 1; SUNITINIB;

ADJUVANT CHEMOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BONE MARROW CELL; CANCER INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR VOLUME;

EID: 79958052123     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.01.030     Document Type: Article

References (37)

1. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006;94:614-9. (Pubitemid 43361889)
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
3. Kaelin Jr WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007;13:680s-4s.
4. Roskoski Jr R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007;356:323-8. (Pubitemid 46452568)
5. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45. (Pubitemid 47338181)
6. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-16. (Pubitemid 36917920)
7. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009;69:2506-13.
8. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52. (Pubitemid 39620069)
9. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103. (Pubitemid 26338628)
10. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79. (Pubitemid 351430364)
11. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007;13:5243-8. (Pubitemid 47510346)
12. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367-77.
13. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21.
14. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009;30:624-30.
15. + myeloid cells. Nat Biotechnol 2007;25:911-20.
16. Dolcetti, L., E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez Gomez, C. Mesa, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40:22-35.
17. Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593-1600.
18. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
19. Ko, J. S., P. Rayman, J. Ireland, S. Swaidani, G. Li, K. D. Bunting, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70:3526-3536.
20. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
21. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514-22.
22. Abe, F., I. Younos, S. Westphal, H. Samson, E. Scholar, A. Dafferner, et al. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. Int Immunopharmacol 10:140-145.
23. Bose, A., J. L. Taylor, S. Alber, S. C. Watkins, J. A. Garcia, B. I. Rini, et al. Storkus. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer.
24. Kujawski, M., C. Zhang, A. Herrmann, K. Reckamp, A. Scuto, M. Jensen, et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 70:9599-9610.
25. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51. (Pubitemid 46020826)
26. Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 2008;112:1832-43.
27. Peranzoni, E., S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello, S. Mandruzzato, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22:238-244.
28. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008;14:8270-8.
29. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553-60.
30. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8. (Pubitemid 40524582)
31. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001;61:4756-60. (Pubitemid 32691887)
32. + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008;14:5884-92.
33. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
34. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546-53. (Pubitemid 47041228)
35. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-43. (Pubitemid 39129439)
36. Huang, D., Y. Ding, M. Zhou, B. I. Rini, D. Petillo, C. N. Qian, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063-1071.
37. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005;175:5351-7. (Pubitemid 41456421)